- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Leigh Purvis Discusses the Burden of High Prescription Drug Costs
The burden of high drug costs is something that everyone with health insurance coverage is facing, explained Leigh Purvis, director, Health Services Research, AARP Public Policy Institute.
The burden of high drug costs is something that everyone with health insurance coverage is facing, explained Leigh Purvis, director, Health Services Research, AARP Public Policy Institute.
Transcript
How does the burden of high prescription drug costs in Medicare have a broader impact than just on Medicare beneficiaries?
This problem is not unique to Medicare. This is something that everyone who has health insurance coverage is facing, and frankly, all Americans are facing. A message we always like to drive home when it comes to prescription drug costs is that it’s an issue that affects everyone. You’re either paying for them at the pharmacy counter, you’re paying for them as part of your premiums or part of your cost-sharing as someone with health coverage, or you’re paying for them through your taxes. Programs like Medicare and Medicaid are spending a lot of money of these products, and that eventually will translate into taxes, and ultimately can turn into either higher taxes or cuts to the programs that people rely on.
How does the drug cost burden facing the US elderly population compare with the elderly population in other, similar countries?
I think high prescription drug costs are a challenge globally, but I think they’re much more so in the United States. We face much higher cost-sharing, we have higher cost-related non-adherence. Just the nature of the health coverage system in the United States is much more fragmented. It makes it harder for them to drive bargains on prices that other countries are able to do just by virtue of the fact that they’re bargaining on the behalf of everyone.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More
